196 results
6-K
EX-99.1
IPHA
Innate Pharma
14 May 24
Innate Pharma Reports First Quarter 2024 Business Update And Financial Results
6:07am
, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office in Rockville, MD, Innate … . These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety
6-K
EX-99.1
IPHA
Innate Pharma
7 May 24
Innate Pharma announces conference call and webcast for Q1 2024 business update
6:03am
and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered … in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies
6-K
EX-99.1
IPHA
Innate Pharma
15 Apr 24
Innate Pharma Announces Advancement Of Sanofi-Developed Nk Cell Engager Sar443579 / Iph6101 Progressing To Phase 2 For Blood Cancer Patients
6:02am
and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients … inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical
6-K
EX-99.1
IPHA
Innate Pharma
15 Apr 24
Current report (foreign)
6:00am
institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered in Marseille, France with a US office … from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including
6-K
EX-99.1
IPHA
Innate Pharma
10 Apr 24
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
6:51am
and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.
Headquartered … in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical
6-K
EX-99.1
qv4jxg3qi0p2b
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
6-K
EX-99.1
edxx8qlprnnocp4m 59
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
6-K
EX-99.1
wmy402
19 Mar 24
Innate Pharma Announces Its Participation To Upcoming Investor Conference
6:33am
6-K
EX-99.1
31as5 p1djmh
14 Mar 24
Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results
7:00am
6-K
EX-99.01
dfa 4p2zooz5
6 Mar 24
Current report (foreign)
6:00am
6-K
EX-99.01
6uovg649 92o1w
6 Mar 24
Current report (foreign)
6:00am
6-K
EX-99.1
9ma7ohj2o6ci6gpynb
21 Feb 24
Innate Pharma Announces Its Participation To Upcoming Investor Conference
6:00am
424B5
v7roe
6 Feb 24
Prospectus supplement for primary offering
5:00pm
6-K
EX-99.1
rh29wmvfii1o29rvzb
12 Jan 24
Innate Pharma S.a. 6-K
6:00am
6-K
lfha39i
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
EX-99.1
53uf17qgx4
4 Jan 24
FDA lifts partial clinical hold on lacutamab clinical programFatal case related to disease progression and unrelated to the treatment
6:01am
6-K
EX-99.1
jzkyxmekdsjtml
4 Jan 24
Innate Pharma 6-K
6:00am